Squarepoint’s Cogent Biosciences COGT Stock Holding History

Squarepoint’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-62,500	Closed	-$488K	–	4697
2024 Q4	$488K	Buy	+62,500	New	+$623K	﹤0.01%	3742

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's COGT Position: Q2 2026 in Review

Squarepoint sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 226,259 shares — an estimated $8.71M sold.

Squarepoint first reported a position in COGT in Q3 2018 and held it in 14 quarters. The position peaked at $8.71M in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Squarepoint reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 226,259 Cogent Biosciences shares in Q2 2026, an estimated $8.71M.
Squarepoint first reported a position in Cogent Biosciences in Q3 2018 and held it in 14 quarters.
Squarepoint's Cogent Biosciences position peaked at $8.71M in Q1 2026.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.